ABBV Stock Technicals: Gains 2.26% on Tuesday, RSI Overbought

AbbVie closed at $289.08, up 2.26% on the day, putting the drugmaker’s shares at their highest level in 20 trading days and close to a three-month peak. The advance makes the stock worth watching: it is backed by a rising trend and positive momentum, but indicators also show buyers may have pushed the price into overbought territory. For international investors, the distinction matters. A share price can keep rising while becoming more vulnerable to a pause or pullback; overbought readings signal strong recent buying, not a guaranteed reversal. AbbVie gained 5.37% over five days and 9.00% over one month, according to market data from the exchange via Yahoo Finance, as of October 21, 2026, at 03:03 WIB.

Trend & Price Action

The price is above its 20-day simple moving average (SMA), at $272.03, and its 50-day SMA, at $264.01. A simple moving average smooths past prices to help show the direction of a trend. The 20-day average’s slope is up 1.95% over five days, reinforcing the evidence that the advance is established rather than confined to a single session. There has been no new moving-average crossover, so the signal comes from the existing price position and rising short-term average, not a fresh technical trigger. The shares are at 100% of their 20-day range, with $289.08 also marking the 20-day resistance level. They are nearing the three-month high of $291.40. That puts AbbVie at a test: a sustained move beyond the recent peak would extend the breakout, while a failure to hold near resistance could bring the focus back to moving-average support. As shown in the chart, price is pressing the upper boundary of the Bollinger band, a range based on recent price variation. The upper band is $290.06, and the reading at 97% of the band’s width places the shares near that ceiling. The band width is 13.3%, described as normal, so the data do not indicate an unusually tight setup poised for a volatility surge.

Oscillators & Momentum

The momentum picture is positive but stretched. The RSI is 70.9, in overbought territory; RSI gauges the pace of recent gains, and readings above 70 are commonly treated as a sign that a move may have run ahead of itself. The Stochastic readings—%K at 93.1 and %D at 83.1—are also overbought. These measures do not dictate that the price must fall, but their alignment suggests the rally may need to consolidate to sustain its pace. The MACD is positive at 6.568, above its 4.969 signal line, with a positive 1.599 histogram. MACD compares shorter- and longer-term price averages to assess momentum; a positive reading above the signal line supports the upward trend. In other words, momentum confirms the direction even as the oscillators warn that the shares are extended.

Volatility, Volume & Levels

Trading volume was 5.175 million shares, close to the 20-day average of 5.015 million, or about 1.0 times normal. That is enough to show the rise was accompanied by ordinary participation, rather than a conspicuous surge in trading. On-balance volume (OBV), which tracks whether volume tends to accompany rising or falling prices, is increasing—another sign that buying pressure has supported the advance. The average true range (ATR) is $7.07, equivalent to 2.4% of the share price. ATR estimates typical price movement, not direction; here it points to moderate volatility and cautions against treating small day-to-day moves as decisive. Resistance stands at $289.08, with the three-month high at $291.40; support over 20 trading days is $259.93. The $272.03 20-day average is a nearer trend reference. If the stock clears and holds above the three-month high, the current strength would gain confirmation. If it retreats, the 20-day average is an intermediate check, while a fall below $259.93 would weaken the short-term technical picture more materially.

Technical Verdict: HOLD

HOLD (wait & see) is the technical verdict: the rising trend, positive MACD and increasing OBV support the advance, but the RSI and Stochastic are overbought and the share price is testing resistance. This balance argues for caution rather than assuming that momentum can continue unchecked. - Ideal entry range: $272.03–$289.08, using the 20-day average as trend support and the current resistance as the upper boundary. - Exit target: $291.40, the three-month high and the next stated price level above resistance. - Stop-loss protection: $259.93, the 20-day support level. - Invalidation condition: The verdict is invalidated if the price falls below $259.93. For non-traders, the chart remains upward-sloping, but its momentum gauges say the rally is already running hot. As of the latest market data, AbbVie is still near its three-month high, while its RSI remains in overbought territory.

Summary Data ABBV

Last price	289.08 USD
Change 1 day / 5 days / 1 month	2.26% / 5.37% / 9.00%
Trend / MA-cross	uptrend / none
SMA20 / SMA50	272.03 / 264.01
RSI (14) / Stochastic %K	70.9 / 93.1
Bollinger %B / ATR	97% / 7.07
Support / Resistance 20 days	259.93 / 289.08
Data as of	21 October 2026 03:03 WIB

Disclaimer: This technical analysis is generated automatically from exchange data (via Yahoo Finance) and indicators calculated by JournalArta, for information and education only. The verdict and the entry, target and stop-loss levels are not investment advice or a solicitation to buy or sell any security. Investment decisions and their risks rest solely with the reader.